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Abstract
We have recently proposed that lipid peroxidation may be a
common mechanistic pathway by which obesity and hypertension
lead to increased renal cell cancer risk. During this exercise, we
noted a risk factor swap between breast and kidney cancer
(oophorectomy and increased parity, detrimental for kidney,
beneficial for breast; high blood pressure, detrimental for kidney,
beneficial for breast when it occurs during pregnancy; alcohol,
beneficial for kidney, detrimental for breast, and so on). We have
subsequently proposed the hypothesis that lipid peroxidation
represents a protective mechanism in breast cancer, and reviewed
the evidence of the role of lipid peroxidation on established
hormonal and non-hormonal factors for breast cancer. Here, we
review the evidence in support of lipid peroxidation playing a role in
the relationships between dietary factors and breast cancer.
Available evidence implicates increased lipid peroxidation products
in the anti-carcinogenic effect of suspected protective factors for
breast cancer, including soy, marine n-3 fatty acids, green tea,
isothiocyanates, and vitamin D and calcium. We also review the
epidemiological evidence supporting a modifying effect of oxidative
stress genes in dietary factor-breast cancer relationships.
Introduction
Lipid peroxidation is a natural metabolic process under normal
conditions. It can be divided into three stages: initiation,
propagation and termination [1]. The initiation phase includes
activation of oxygen and is rate limiting. Polyunsaturated fatty
acids (the main component of membrane lipids) are
susceptible to peroxidation. Lipid peroxidation is one of the
most investigated consequences of reactive oxygen species’
(ROS) actions on membrane structure and function. The idea
of lipid peroxidation as a solely destructive process has
changed during the past decade. It has been shown that lipid
hydroperoxides and oxygenated products of lipid peroxidation
degradation as well as lipid peroxidation initiators (that is,
ROS) can participate in the signal transduction cascade
[2,3], the control of cell proliferation, and the induction of
differentiation, maturation, and apoptosis [4-6]. It has been
shown that lipid peroxidation and ROS are triggers and
essential mediators of apoptosis, which eliminates pre-
cancerous and cancerous, virus-infected and otherwise
damaged cells that threaten our health [7-10]. In addition,
although the essential n-6 fatty acid linoleic acid has been
shown to increase breast cancer in experimental studies,
other n-6 fatty acids (such as conjugated linoleic acid, and
gamma linolenic acid) and n-3 fatty acids (such as
eicosapentaenoic acid, docosahexaenoic acid (DHA), and
alpha-linolenic acid) have been shown to inhibit the growth of
breast cancer in vivo and  in vitro and this inhibition is
correlated with the extent of lipid peroxidation generated in
tumor cells [11]. This suppression of cancer growth is
enhanced by pro-oxidants and eliminated by antioxidants, and
this elimination is proportional to the inhibition of lipid
peroxidation products by antioxidants [11].
We have recently proposed the hypothesis that lipid
peroxidation represents a protective mechanism in breast
cancer, and reviewed the evidence of the role of this process
on established reproductive, hormonal, and non-hormonal
factors for breast cancer [11]. There is some supporting
evidence that lipid peroxidation may play a role in the
potential anticarcinogenic effects of other breast cancer
factors, including soy [12-18], marine n-3 fatty acids [19],
isothiocyanates (ITCs) [20-23], green tea [24-28], and
vitamin D [29] and calcium [30,31]. Here, we review the
evidence in favor of lipid peroxidation playing a role in these
relationships between dietary factors and breast cancer. We
also review the evidence favoring a modifying effect of
oxidative stress genes in these dietary factor-cancer
associations.
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Lipid peroxidation: beneficial, detrimental or
both?
There is ample evidence supporting a causative role of lipid
peroxidation in selected human cancers, including kidney,
liver and skin, and in degenerative diseases. In experimental
models, estrogen treatment induces lipid peroxidation and
subsequently increases the incidence of renal cell cancer
[32,33]. Because estrogen is a risk factor for breast cancer, it
has been hypothesized, based on this model, that lipid
peroxidation may be one mechanism by which estrogen
increases breast cancer risk [11]. But estrogen induces renal
cancer or liver cancer in this experimental model, not breast
cancer. Indeed, lipid peroxidation may be a relevant
mechanism for renal carcinogenesis, a concept that we have
proposed and that is strongly supported by experimental and
epidemiological data [32-34], but there is a lack of
experimental models in support of estrogens increasing lipid
peroxidation and subsequently inducing breast cancer
development [11]. In contrast, there is evidence favoring lipid
peroxidation as an anticarcinogenic mechanism in breast
cancer. A consideration of the literature on animal and in vitro
studies suggests that an influence on breast cancer
protection relates to the generation of lipid peroxidation
products [11].
We believe that the beneficial or detrimental effects of lipid
peroxidation on cellular structures may depend on several
factors [11], such as baseline levels of ROS (inducers of lipid
peroxidation), and the type of tissue, that is, slowly versus
rapidly proliferating tissue, in which ROS exert their action
[11], as we have discussed in detail in our prior
communication [11].
Role of lipid peroxidation on the relationships
between dietary factors and breast cancer
In general, the associations between dietary factors and
breast cancer remain controversial in the epidemiological
literature, but there is some support for a lipid peroxidation
pathway and a protective effect from in vitro studies [11]. It is
possible that the lack of consideration of the lipid
peroxidation pathway and the implied modifying effects of
related gene polymorphisms may account for some of the
lack of consistency in previous epidemiological studies. We
believe that many dietary factors have both antioxidant and
pro-oxidant properties, but what is important is which
property is responsible for their anti-cancer effect. We raise
the possibility that a deficiency in lipid peroxidation, not an
increased antioxidant potential, may be detrimental for breast
cancer. This does not imply that antioxidants are detrimental
for breast cancer, as different antioxidants may inhibit
different cell structures with different affinity and intensity,
such as lipids, proteins or other cell constituents. Thus, the
lipid peroxidation theory does not contradict the fact that, in
studies investigating blood levels of antioxidants and breast
cancer risk, for example, the evidence of a benefit for
protection is not clear but neither is evidence of harm.
In the following sections we consider the dietary factors n-3
fatty acids, n-6 fatty acids, soy, ITCs, tea, and vitamin D and
calcium in light of the lipid peroxidation mechanism.
Marine n-3 fatty acids
Eight cohort studies, conducted in Norway [35], Japan [36],
Europe [37], the US [38-41], and Singapore [42], have
examined fish or marine n-3 fatty acids intake in relation to
breast cancer; only one of them, the study from Singapore,
found an association [42].
Results from case-control studies of marine n-3 fatty acids
(eicosapentaenoic acid and DHA) measured in adipose
tissue are mixed [43-47]. Maillard and colleagues [45] found
strong inverse associations for DHA, and for the marine n-
3/total n-6 fatty acids ratio. In a case-control study conducted
in Finland, DHA level in breast adipose tissue, along with its
dietary intake, were significantly lower in breast cancer
patients compared to control patients, suggesting a
protective effect of DHA in the risk of breast cancer [43].
Also, a case-control study conducted across five European
countries found a decreased risk of breast cancer with an
elevated ratio of marine n-3 fatty acids to total n-6 fatty acids
in four of five centers [44]. In contrast to these findings, two
case-control studies conducted in the US found no
consistent association between n-3 fatty acid levels in
adipose tissue and breast cancer risk [46,47].
The reason for the discrepancy between the US and
European studies remains unresolved. One hypothesis is
these discrepancies may be due to differences in ranges of
fish intake across the various populations [42]. Another
hypothesis is that the inconsistencies may be due in part to
interactions between n-3 fatty acids and antioxidant
compounds in the diet, affecting their roles in breast cancer
risk [45,48,49]. As pointed out above, data from experimental
studies suggest that the strength of the association with
marine n-3 fatty acids may be reduced in the presence of high
antioxidant intake because the latter inhibit the formation of
lipid peroxidation products, which have been proposed as the
proximal anti-carcinogens [48,50]. In fact, several experimental
studies showed that the suppression in cancer growth with n-
3 fatty acids is enhanced by pro-oxidants [51] and eliminated
by antioxidants such as vitamin E [11,18,51,52]. This
suggests that the anti-cancer effect of n-3 fatty acids is
mediated, at least in part, by lipid peroxidation products and
emphasizes the importance of the potential interactions of
anti- and pro-oxidant compounds with marine n-3 fatty acids
[45]. Maillard and colleagues [45] suggested that the lack of
an association between marine n-3 fatty acids and breast
cancer risk in US studies [39,46,47,53] may be due, in part, to
the interfering role of antioxidant vitamins, which are commonly
taken as supplements in the US [45,54].
As mentioned above, we recently published the first set of
prospective results linking intake of marine n-3 fatty acids toPage 3 of 11
(page number not for citation purposes)
breast cancer protection in Singapore Chinese women [42].
In our study, relative to the lowest quartile of marine n-3 fatty
acid intake, individuals in the higher 3 quartiles exhibited a
26% reduction in risk of breast cancer (relative risk = 0.74,
95% confidence interval (CI) = 0.58, 0.94). We also have
published the first set of results in humans implicating the
peroxidation products of marine n-3 fatty acids as the
proximal anticarcinogens [19], a notion strongly supported by
experimental evidence [18,49,50,52,55-57]. Glutathione-
associated metabolism is a major mechanism for cellular
protection against agents that generate oxidative stress,
acting by eliminating products of lipid peroxidation [58,59].
Therefore, we hypothesized that individuals possessing the
low activity genotypes of GSTM1, GSTT1 and/or  GSTP1
(that is, GSTM1-null, GSTT1-null and GSTP1 AB/BB geno-
types, respectively) [60,61] may exhibit a stronger inverse
association between marine n-3 fatty acids and breast cancer
than their high activity counterparts. This hypothesis was
supported by study results [19].
N-6 fatty acids
Meta-analysis of case-control and prospective cohort studies
on breast cancer have failed to demonstrate a convincing link
between n-6 fatty acids and breast cancer development [62-
64]. In contrast, diets containing n-6 fatty acids have been
shown to induce breast cancer in experimental studies [65].
N-6 fatty acids act as competitive inhibitors of n-3 fatty acids
in fat metabolism, and it has been shown that the stimulatory
or inhibitory effect of n-6 or n-3 fatty acids in experimental
mammary carcinogenesis is abrogated by the addition of the
other type of fatty acid [66-68]. Experimental studies have
shown that a diet high in n-6 fatty acids decreases the
concentrations of marine n-3 fatty acid-induced lipid
peroxidation products in breast cancers to the lowest levels,
and that the lower this concentration, the bigger the tumor
volumes resulting from n-6 fatty acid administration [52,55].
This experimental evidence is consistent with our results [42]
showing that n-6 fatty acids increase breast cancer risk only
among women with a low intake of marine n-3 fatty acids; that
is, when concentrations of n-3 fatty acid-induced beneficial
lipid peroxidation byproducts are low. So one possible
mechanism whereby n-6 fatty acids increase breast cancer
growth is the decreasing of the beneficial lipid peroxidation
products derived from n-3 fats.
Soy
At least 13 epidemiological studies have assessed the direct
relationship between the individual dietary intake of soy
products and the risk of breast cancer (reviewed by Peeters
and colleagues [69]). Overall, results do not show protective
effects, with the exception maybe for women who consume
phytoestrogens at adolescence or at very high doses
[70-72]. Only 4 of these 13 studies were prospective, and
none of them found statistically significant breast cancer
reductions. The only prospective study with urinary measure-
ments taken before breast cancer occurrence was done in a
Dutch postmenopausal population and showed a non-
significant breast cancer risk reduction for high excretion
[73]. Soy phytoestrogen levels in the Dutch study were very
low, as were those in another recent study [74]. In
conclusion, none of the five prospective studies assessing
the effects of phytoestrogens on breast cancer risk found
protective effects [69]. However, none of these studies took
into account mechanistic pathways by which soy can
operate, including the lipid peroxidation pathway, for example,
analyzing soy oil, where lipid peroxidation may be higher.
Soybean and canola oils are the primary sources of alpha
linolenic acid (ALA; an oxidizable n-3 fatty acid) in the diet
[75]. Soybeans contain lipoxygenase, which is an oxidizing
enzyme [76] that catalyzes lipid peroxidation [77]. It has been
shown that soybean lipooxygenase increases peroxidation of
membrane lipids [78] and oxidizes low-density lipoproteins
[12,13,79]. A soybean oil diet fed to rabbits and rats caused
an increase in lipid peroxidation compared to controls [14-
16]; this increase is accenuated by protein insufficiency [17].
Limited  in vitro data suggest that the decreased breast
cancer risk associated with ALA may be related to increased
lipid peroxidation products [18]. The addition of ALA to
breast cancer cells caused an increase in the formation of
lipid peroxidation products in the cell lipids, and their content
was correlated with the capacity of arresting cell growth [18].
The addition of the antioxidant vitamin E to the ALA-
supplemented cancer cells diminished formation of lipid
hydroperoxides and restored cell growth [18]. In addition,
vitamin E also suppressed the inhibitory effect of ALA on
tumor growth in different models of mammary carcinogenesis
in rats [51]. Administration of oxidative compounds to diets
high in ALA led to an inhibition of tumor growth in chemically
induced mammary carcinogenesis [51].
In an experimental study, a fermented soymilk product
induced generation of ROS and caused apoptotic cell death
in MCF-7 breast cancer cells. Growth inhibition and ROS
generation induced by fermented soymilk product could be
inhibited by catalase and deferoxamine, indicating that the
ROS production probably was the cause of this apoptotic
cell death [80]. The opposite has also been reported, that is,
soy having an antioxidant effect [81]. The effect appears to
be indirect as the antioxidant potency of isoflavones is weak
and the effects appear to be due more to effects on signaling
pathways that induce antioxidant enzyme systems or
suppress enzymes that produce ROS.
Isothiocyanates
In animal models of breast cancer, tumor growth is inhibited
by brassica consumption, or ITC or indole-3-carbinol admini-
stration [82-85]. In humans, the relationship between brassica
consumption and breast cancer risk is uncertain. Investiga-
tions have found null associations [86-89], protective but not
statistically significant associations [90-92], and statistically
Available online http://breast-cancer-research.com/content/9/1/201significant protective associations [93,94]. The failure to
consider the lipid peroxidation pathway and the implied
modifying effects of oxidative stress-related genes may
explain the lack of consistency among human studies. ITCs
are potent inducers of lipid peroxidation [20-23]. There is
suggestive evidence that ITC-induced apoptosis is mediated
by oxidative stress/lipid peroxidation products [22,23]. Depletion
of the antioxidant glutathione significantly accelerated ITC-
triggered apoptosis [23]. ITCs are also able to induce
glutathione  S-transferases (GSTs) and/or other antioxidant
enzymes through the stress-signaling pathway involving
oxidative stress [22]. Oxidizing agents enhanced ITC-induced
ROS production and ITC-induced GST activities, whereas
antioxidants inhibited both [22]. In humans, one study has
shown that individuals with genetic polymorphisms encoding
lower or no activity in antioxidant enzymes (GSTM1, GSTT1)
experience more breast cancer protection from ITCs than
those with common alleles [95], putatively because more
beneficial peroxidation agents could reach the cancer cells
and cause damage (see below). However, this finding has not
been confirmed in a second study [94].
Tea
Published epidemiological studies overall suggest that green
tea but not black tea consumption is related to decreased
risk of breast cancer [96]. A recent meta-analysis [96]
included three cohort and one population-based study for
green tea, while five cohort and eight case-control studies
were analyzed for a link between black tea and breast cancer.
Overall summary odds ratio showed an approximately 20%
statistically significant reduction in risk of breast cancer
associated with high intake of green tea. No such protective
effect was found for black tea.
Both green and black tea have demonstrated inhibitory
activities against chemically induced mammary tumors in
experimental animals [97-99]. Epigallocatechin gallate (EGCG),
one of the main constituents of tea that is thought to be
responsible for its anticancer properties, not only can function
as an antioxidant, but it possesses the chemical property of a
pro-oxidant. Previous studies on the antioxidative properties
of EGCG have demonstrated that its effects include both
trapping of ROS as well as inhibition of lipid peroxidation
[25]. However, after neutralizing the peroxyl and/or other
radicals, EGCG itself could be converted to a phenoxyl
radical [26]. Experimental studies in HT-29 colorectal cancer
cells have indicated that oxidative stress is involved in
EGCG-induced cell death. The chemical property of EGCG
as a potential pro-oxidant is highlighted by the blocking
effects of reduced glutathione and N-acetyl-L-cysteine
against EGCG-induced mitogen-activated protein kinase
activation, cytochrome c release and cell death [24]. In a
recent study [100], Wu and colleagues noted that the
protective effect of tea on breast cancer was confined to
those possessing the low-activity genotype of the antioxidant
catechol-O-methyl transferase (COMT), putatively because
more beneficial peroxidation agents could reach the cancer
cells and cause damage.
Vitamin D and calcium
Increased mammographic breast density is strongly
associated with the risk of breast cancer [101]. A recent
study showed that an increased intake of vitamin D and
calcium was associated with decreases in mammographic
breast density [102].
Evidence from both in vitro and  in vivo studies has
demonstrated that vitamin D compounds can inhibit the
growth of breast cancer cells [103]. The anticancer activity of
the hormonal form of vitamin D, 1,25-dihydroxycholecalciferol
(1,25-(OH)2D3) [104], is associated with inhibition of cell
cycle progression, induction of differentiation, and apoptosis.
In addition, 1,25(OH)2D3 may exert some of its activity by
cooperating with other anticancer agents. 1,25(OH)2D3 and
its synthetic analogues increased the susceptibility of cancer
cells to the cytotoxic/cytostatic action of tumor necrosis
factor [105-107], interleukin 1, interleukin 6 [108], doxo-
rubicin, menadione [109], and radiation [110]. A feature
shared by these agents whose potency is increased by
1,25(OH)2D3 is their ability to bring about excessive ROS
generation in their target cells [111-113]. This common
feature suggests the involvement of ROS in the interaction
between 1,25(OH)2D3  and these agents. In addition, the
potentiation of the cytotoxic/cytostatic action of the chemo-
therapy drug doxorubicin or cytokines by 1,25(OH)2D3 is
markedly inhibited by the antioxidant N-actylcysteine
[108,109]. Importantly, it has recently been shown that
1,25(OH)2D3, acting as a single agent, is also a pro-oxidant
in cancer cells [29]. These findings indicate that
1,25(OH)2D3 causes an increase in the overall cellular redox
potential that could translate into modulation of redox-
sensitive enzymes and transcription factors that regulate cell
cycle progression, differentiation, and apoptosis [29].
The evidence that calcium or dairy products are associated
with breast cancer risk is still open to debate. A recent
pooled analysis of cohort studies failed to find an association
[114], but some studies found some limited evidence of a
protection [115,116]. As mentioned above, a recent study
showed that an increased intake of vitamin D and calcium
was associated with decreases in mammographic breast
density [102]. Boyapati and colleagues [116] recently
reported that dietary calcium intake was negatively
associated with the risk of breast cancer in both premeno-
pausal and postmenopausal women. In the Nurses’ Health
Study both calcium and dairy product intake was associated
with a survival benefit for women with breast cancer [117,118].
After ingestion, calcium absorption can occur via an active
transport process (transcellular) that requires the action of
1,25-(OH)2D3, or by passive diffusion (paracellular), which is
a vitamin-D-independent process. The vast majority of
Breast Cancer Research    Vol 9 No 1 Gago-Dominguez et al.
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cellular pathway, and thus upon the activity of 1,25-(OH)2D3
[119]. Therefore, it is difficult to separately establish the
potential effects of these two nutrients on health and disease,
and it is of clear importance to evaluate the effects of these
nutrients simultaneously [120].
There are several proposed mechanisms of action for
calcium, including inhibition of cellular proliferation [121,122],
and induction of apoptotic cell death [123,124] through
oxidative stress [30,31,125,126]. It is, however, unclear how
calcium, especially through intake, might have these
hypothesized effects when blood levels are so tightly
regulated. It seems that the elevation in the intracellular free
calcium, which correlates with the induction of apoptosis in
breast cancer cells, is brought about by vitamin D
compounds [124,127-129]. The latter studies further support
the need for investigations that consider the role of vitamin D
and calcium simultaneously. The effects of these two
nutrients may be strongly related to one another, and
separate studies may not capture their true effects on breast
neoplasia.  Generally, apoptotic cell death is triggered by
intracellular signaling pathways, including a rise in intracellular
free calcium [30], the generation of ROS and membrane lipid
peroxidation products [125,126]. Calcium strongly stimulates
the release of ROS [130] (including superoxide anion [131-
133], hydrogen peroxide and hydroxyl radicals [134]), which
induce membrane lipid peroxidation [130]. This calcium-
dependent increase in membrane lipid peroxidation triggers
apoptotic cell death [30,31,125,126]. Calcium, lipid
peroxidation and apoptosis are possibly interlinked through
signals, as is evident from the increased activity of nuclear
factor kappa-B, a critical molecule in oxidative-stress-induced
apoptosis, and generation of nitric oxide [135].
Oxidative stress metabolism: modifying
effect of oxidative stress genes on the
relationships between dietary factors and
breast cancer
If lipid peroxidation/ROS plays a role in breast cancer
protection, it is likely that differences in the ability to protect
cells from these beneficial products will determine, to some
degree, the effect of these protective factors on breast
cancer. Critical to the effects of products of lipid peroxidation
are the enzymatic and non-enzymatic defenses that protect
the cells from oxidative stress through reduction of reactive
molecules, including mitochondrial manganese superoxide
dismutase (MnSOD), glutathione peroxidase, and catalase.
These enzymes form the first line of defense against
superoxide and hydrogen peroxide [136]. The resultant
secondary oxidation products may still damage DNA, proteins
and lipid, and require further detoxification. This second line
of defense against ROS/lipid peroxidation is provided by
enzymes such as the GSTs. Several examples support a
modifying effect of oxidative stress genes on the relationships
between dietary factors and breast cancer.
We will summarize next the potential modifying roles of
oxidative stress genes on the relationships between n-3 fatty
acids, ITCs, and tea and breast cancer.
Glutathione S-transferases GSTM1, GSTT1, and GSTP1
Glutathione-associated metabolism is a major mechanism for
cellular protection against agents that generate oxidative
stress, protecting cells against cytotoxic products of lipid
peroxidation [58,59]. GSTs are induced under conditions of
oxidative stress, and alpha-, pi-, mu-, and theta-class GSTs
are active in detoxification of numerous products, including
reactive oxidant damage to DNA and lipids, such as organic
epoxides, lipid hydroperoxides, and unsaturated aldehydes
[58,59]. Individuals lacking these enzymes may have reduced
removal of lipid peroxidation products and, thus, may
experience higher cancer protection, as supported by results
from our study [19]. We found that women with genetic
polymorphisms causing lower or no activity in detoxifying
genes (GSTM1, GSTT1, GSTP1) had more protection from
marine n-3 fatty acids than those with common alleles,
putatively because more cytotoxic peroxidation agents could
reach the cancerous and pre-cancerous cells and cause
damage. Recent results on cyclin D1 (CCND1), an
intracellular cell-cycle regulatory protein with checkpoint
function, and breast cancer risk further support our hypo-
thesis of an oxidative stress-induced apoptosis mechanism
underlying the diet-induced breast cancer protection.
CCND1 has been shown to modulate growth arrest and
apoptosis following exposure to ionizing radiation oxidative
DNA damage [137,138]. In a recent study, the protective
effect of the heterozygous CCND1 GA genotype on breast
cancer risk was restricted to situations of elevated oxidative
stress, characterized by absence of antioxidant GSTM1 and
GSTT1 enzymes [139]. In addition, CCND1 also interacted
with marine n-3 and n-6 fatty acids to influence breast cancer
risk, with the protection being restricted to women with a high
intake level of n-6 fatty acids, or a low intake level of marine n-
3 fatty acids [139].
Similarly, ITCs’ protective effect on breast cancer found in
some studies [95], although not in others [94], was mainly
confined to those possessing the low activity genotype of
GSTs. There is suggestive evidence that ITC-induced
apoptosis is mediated by oxidative stress/lipid peroxidation
products [22,23]. Seow and colleagues [140] also found that
individuals with genetic polymorphisms causing lower or no
activity in antioxidant genes (GSTM1, GSTT1, GSTP1) had
more colorectal cancer protection from ITCs than those with
common alleles. These findings were attributed to the direct
effects of GSTs on ITC excretion [140]. However, we
proposed that the oxidative products of ITCs may be
responsible, at least in part, for their anti-cancer effect, and
this would explain why the protection appears more
pronounced among subjects with lowest antioxidant GST
activity [11], in parallel with what we had described for the
marine n-3 fatty acids/GST/breast cancer relationship [19]. A
Available online http://breast-cancer-research.com/content/9/1/201
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CCND1 A870G polymorphism on colorectal cancer risk was
found to be modified by GSTM1, GSTT1, and GSTP1
genotypes and ITC intake [141], further supports our
proposed oxidative stress-based hypothesis. In that study, the
presence of at least one CCND1 A-allele was associated
with increased risk among low dietary ITC consumers with a
high activity GST profile. In contrast, the presence of at least
one A-allele was associated with a decreased risk among all
remaining subjects, which led the investigators to
hypothesize that subjects with low intake levels of ITCs and
functional GST enzymes are left with low levels of pro-
oxidative, anti-cancer acting ITCs at a cellular level [141].
The genetic polymorphisms of GSTM1 and GSTT1 have also
been found to influence the risk-enhancing effect of alcohol in
breast cancer. Zheng and colleagues [142] found that breast
cancer risk was about 7-fold increased for postmenopausal
women with the GSTT1-null genotype who consumed more
than 250 kg of spirit equivalents. In our prior study [19], the
GSTT1-null genotype was associated with a 30% reduced
risk of breast cancer. This finding is consistent with another
study that reported a decreased risk among premenopausal
women lacking the GSTT1 gene [60]. Most studies have
found no increased risk for breast cancer with null genotypes
for GSTM1 and/or GSTT1 (reviewed in [61]), although some
positive associations have been reported [143-147].
Catechol-O-methyl transferase
COMT is an antioxidant enzyme that catalyses the methylation
of hydroxylated sites on the aromatic ring of catechol
compounds, which prevents their conversion to semiquinones
and quinines and, therefore, blocks the generation of ROS
[148-150]. In a recent study, the COMT-L low activity allele-
containing genotypes (HL or LL) tended to be at decreased
risk of developing breast cancer, especially the advanced
stage of disease in premenopausal women and local carcinoma
in postmenopausal women [151,152]. A tendency of decreasing
risk can also be seen for both pre- and postmenopausal
women in the study of Millikan and colleagues [153]. Similarly,
in the case-control study of Lavigne and colleagues [154], a
tendency of decreasing risk was seen among premenopausal
women, although the results were based on a rather small
number of subjects. Thompson and colleagues [155]
observed increased risk for premenopausal women carrying
the COMT-L allele-containing genotypes and decreased risk
for postmenopausal women with these genotypes. Among
Asian-American women in Los Angeles, the protective effect
of tea in breast cancer was mainly confined to those
possessing the low activity genotype of COMT [100]. A
recent study was conducted among breast cancer families
participating in the Metropolitan New York Registry, one of the
six centers of the Breast Cancer Family Registry [156]. The
study found that COMT  genotypes were not statistically
significantly associated with breast cancer risk, although the
study population was of modest size (160 sib-ships).
Manganese superoxide dismutase
MnSOD is an antioxidant enzyme that is induced by free
radical challenge, such as marine n-3 fatty acid-induced lipid
peroxidation [136,157,158], and inhibits polyunsaturated
fatty acid-induced lipid peroxidation and the subsequent
killing of human breast cancer cells [159]. In the
mitochondrion, MnSOD catalyzes the dismutation of two
superoxide radicals, producing hydrogen peroxide and
oxygen. A substitution variant in the mitochondrial targeting
sequence was found that changes the amino acid codon at
the -9 position in the signal peptide from valine to alanine
[160-162]. Hiroi and colleagues [163] reported that
processing efficiency of the valine-type SOD leader peptide
in the presence of mitochondria was significantly lower than
that of the alanine-type, which may reduce protection against
superoxide radicals. This decrease in the efficiency of
transport into mitochondria for the valine isoform of the
protein may result in increased ROS [160,163]. An
association between the valine allele with lung cancer risk
has been reported in a recent study [164]. Contrarily, an
association between the alanine allele and risk of breast
cancer has been found in three studies, two conducted in the
US [162,165] and one in Finland [166]. In the study by
Ambrosone and coworkers [162], premenopausal women
who were homozygous for the alanine allele had a four-fold
increase in breast cancer risk in comparison to those with
one or two valine alleles [162]. Risk was most pronounced
among women who consumed below the median amount of
fruit and vegetables and of ascorbic acid and α-tocopherol. In
addition, in the Finnish study, MnSOD genotypes containing
the alanine allele were found to be associated with a 1.5-fold
(95% CI = 1.1, 2.0) increased risk of breast cancer compared
with those homozygous for the valine/valine genotype [166].
The association between this polymorphism and breast
cancer risk was weaker in the other US study (odds ratio =
1.27; 95% CI = 0.91, 1.77) [165], and no association was
found in a case-control study within the Breast Cancer Family
Registry [167]. However, recent results suggest that this
polymorphism is also associated with breast cancer risk
among Chinese in Shanghai [168].
Conclusion
Accumulating evidence suggests that oxidative stress-
induced apoptosis may play an important role in the anti-
carcinogenic effect of several chemopreventive agents,
including retinoids, nonsteroidal anti-inflammatory drugs,
polyphenols, tamoxifen, vanilloids, and rotenoids [169]. In this
review, we describe how several breast cancer chemo-
preventive factors may exert their anti-cancer effect through
lipid peroxidation-induced apoptosis, including marine n-3
fatty acids, soy, ITCs, vitamin D and calcium. We also
describe the modifying effect of oxidative stress-related
genes such as GSTM1, GSTT1, GSTP1, CNDN1, and
COMT in the relationships between marine n-3 fatty acids,
ITCs, and tea and breast cancer. We believe that the lack of
consideration of the lipid peroxidation pathway and the
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account for some of the lack of consistency in previous
epidemiological studies of diet and breast cancer. In addition,
because several of the dietary factors discussed in this
manuscript have been shown to have multiple cellular effects,
not only lipid peroxidation-related effects, we believe that it
will be important to study the cross-talk between the lipid
peroxidation pathway and other pathways, such as estrogen,
insulin resistance, inflammation, and possibly other pathways.
The lipid peroxidation hypothesis might be further investiga-
ted by measuring the levels of lipid peroxidation markers such
as F2 isoprostanes, which comprise the ‘gold standard’
marker of oxidative stress in vivo, in fluid nipple aspirate or
breast tissue of women with breast cancer, and compare the
values with those from control women.
Our hypothesis has practical implications for breast cancer
prevention. Lipid peroxidation could be proven to be a pre-
diagnostic marker for breast cancer. Lipid peroxidation levels
in breast ductal cells may represent a promising cancer
biomarker to detect, through non-invasive methods such as
nipple fluid aspirate sampling, for example, women at high risk
for breast cancer. In addition, a better understanding of the
relationship between breast cancer risk factors and oxidative
stress/lipid peroxidation-related biomarkers and genes may
prove useful in identifying the dietary or non-dietary exposure-
genotype combinations that put women at the lowest risk. In
addition, lipid peroxidation markers could also be used as
indicators of prognosis. Decreased plasma malondialdehyde
(MDA), another lipid peroxidation marker, has been found to
be significantly associated with severity of prognosis factors
for breast cancer. MDA concentrations were significantly
lower in the plasma of patients with large tumors or in whom
nodes and/or metastasis were present [170-172].
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